Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.36 |
| ▸ | STK25 | O00506 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 10/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675896 | 0.87 | RET (0.37) | CCNE1CDK2RORCLCKRET | |
| SCHEMBL16682113 | 0.87 | CRHR1 (0.38) | CACNA1ICRHR1STK25CCNE1CDK2 | |
| SCHEMBL18556891 | 0.83 | RET (0.37) | CACNA1ICRHR1STK25CCNE1CDK2 | |
| SCHEMBL16682107 | 0.81 | RET (0.37) | CACNA1ICRHR1STK25CCNE1CDK2 | |
| SCHEMBL18556902 | 0.80 | CCNE1 (0.39) | CRHR1CCNE1CDK2RET | |
| SCHEMBL16682117 | 0.80 | RET (0.36) | CACNA1ICRHR1STK25CCNE1CDK2 | |
| SCHEMBL16682120 | 0.79 | NPY5R (0.38) | CCNE1CDK2LCKRETSRC | |
| SCHEMBL16682078 | 0.79 | CACNA1I (0.35) | CACNA1ICRHR1CCNE1CDK2RORC | |
| SCHEMBL18556916 | 0.78 | CYP2D6 (0.46) | CRHR1CNR2 | |
| SCHEMBL16682168 | 0.78 | P2RX7 (0.37) | STK25CCNE1CDK2LCKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | CACNA1I 3911/4885CRHR1 4430/4885STK25 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.